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Failure of infrainguinal bypass grafts remains,
despite expert surgeons and meticulous surgical
techniques, a matter of concern for both patients
and surgeons. In patients not treated postoperative-
ly with antithrombotic agents, 28% to 45% of all
bypass grafts will occlude in the first year after oper-
ation, most of them in an early stage.1-4 Moreover,
patients after peripheral vascular surgery are not only
threatened by the consequences of impaired blood
flow to the lower extremities but also by the gener-
al complications of vascular disease from atheroscle-
rotic origin. Cardiovascular and cerebrovascular dis-
ease and death occur far more often in these patients
than in normal subjects.5-9
In 1975, the first randomized controlled trial
(RCT) showed the protective action of aspirin on
thromboembolic events in patients after infrainguinal
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Purpose: We sought to determine the efficacy of antiplatelet therapy and oral anticoagu-
lants in maintaining graft patency and preventing ischemic complications in patients
after infrainguinal bypass surgery.
Methods: We performed a meta-analysis of randomized controlled trials of aspirin with or
without other antiplatelet therapy and oral anticoagulants after infrainguinal bypass
surgery. Outcome measures studied were graft occlusion, stroke, myocardial infarction,
vascular and total mortality, and the composite outcome of stroke, myocardial infarc-
tion, and vascular mortality.
Results: Five trials of antiplatelet therapy versus placebo were included. The relative risk
(RR) for occlusion was 0.78 (95% CI, 0.64-0.95). For prevention of stroke, myocardial
infarction, and death, and for the composite outcome, no significant effect was mea-
sured. Only one trial of oral anticoagulants versus control treatment was included. The
RR for occlusion was 0.55 (95% CI, 0.30-0.99), and that for amputation was 0.30 (95%
CI, 0.10-0.87). The mortality rate did not differ significantly between the groups. One
trial of oral anticoagulant therapy plus aspirin versus aspirin alone in high-risk patients
was included. The RR for occlusion was 0.38 (95% CI, 0.15-0.95). There were no sig-
nificant differences for prevention of amputation, myocardial infarction, and death
between the groups.
Conclusion: Antiplatelet therapy and oral anticoagulants reduce the risk of graft occlu-
sion. Oral anticoagulant therapy appears to be the more effective treatment in high-risk
patients. Data on the reduction of the risk of stroke, myocardial infarction, and death
are inconclusive. Evidence for the beneficial effects of antiplatelet and oral anticoagulant
therapy after infrainguinal bypass surgery is based on a small number of trials only.
There is no proof as to which modality is the most effective in the prevention of graft
occlusion and ischemic events in patients after infrainguinal bypass surgery, which is rea-
son for a randomized comparison of aspirin with oral anticoagulants. (J Vasc Surg
1999;30:701-9.)
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bypass surgery.10 Many RCTs studying the efficacy of
antiplatelet therapy in maintaining vascular patency in
various categories of patients followed, and most of
them were pooled in an impressive meta-analysis by
the Antiplatelet Trialists’ Collaboration.11 However,
the efficacy of aspirin after infrainguinal bypass
surgery to prevent occlusions and other vascular com-
plications is less frequently studied.
Besides aspirin, oral anticoagulants seem to be
effective antithrombotic agents in these patients.
Nevertheless, RCTs regarding these regimens are
even more limited.
Patients with peripheral arterial occlusive disease
are prone to various ischemic events caused by affect-
ed arteries in other parts of the body. The composite
outcome of ischemic events is the most important
outcome for patients with peripheral vascular disease.
Therefore we are interested in the long-term effects
of antithrombotic therapy on graft occlusion, as well
as on other vascular events. We undertook a meta-
analysis to assess the impact of aspirin and of oral
anticoagulants on occlusion of bypass grafts, and the
occurrence of stroke, myocardial infarction, vascular
and total mortality, and the composite outcome of
stroke, myocardial infarction, and vascular mortality
after infrainguinal bypass surgery.
METHODS
Materials. The goal of this systematic review
was to analyze all unconfounded RCTs of aspirin,
with or without other antiplatelet therapy, and of
oral anticoagulants in patients after infrainguinal
bypass surgery. A search of the Medline database was
done to identify trials published in any language
after 1966. Key words that were searched included
aspirin, acetylsalicylic acid, antiplatelet, (oral) anti-
coagulants, anticoagulation, phenprocoumon, war-
farin, peripheral vascular surgery, bypass surgery, and
bypass graft. This electronic database search was sup-
plemented by manual search of bibliographic refer-
ence lists in review articles and original articles.
Trials were included in the analysis if randomiza-
tion of patients was adequate in a way that preclud-
ed prior knowledge of the next treatment allocation,
if they were unconfounded such that one treatment
group differed from the other only in the treatment
of interest, if duration of treatment was longer than
6 months, and if they reported the total number of
occlusions systematically, allowing intention-to-treat
analysis.
Trials were excluded if randomization was not
concealed (eg, by alternation) because any prior
knowledge of the next treatment allocation may lead
to bias. Trials were also excluded that were consid-
ered to be confounded (ie, where the compared
treatment included other regimens than aspirin with
or without other antiplatelet therapy or oral antico-
agulants). Trials including patients after central
reconstructions and after thromboendarterectomy
were also excluded.
Data on initiation and length of therapy, length
of follow-up, indication for surgery, type of bypass,
and graft material were abstracted for all included
studies.
Outcome measures. The primary outcome
measure was graft occlusion. Secondary outcome
measures sought were stroke, myocardial infarction,
vascular mortality, total mortality, and the composite
outcome of stroke, myocardial infarction, and vascu-
lar mortality. We used the definitions of the outcome
events as used by the authors of the original studies.
Information about medication-related bleeding com-
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Table I. Design characteristics of the included trials
Trial Green13 Goldman14 Kohler15
Medication A975, A + D225, P A900 + D225, P A975 + D225
Start of medication Two days preoperative Two days preoperative First day postoperative
No. of patients randomized 16, 16, 17 22, 31 (21, 28) 50, 50 (44, 44)
(with follow-up)
Months of treatment 12 12 24
Months of follow-up 12 12 24
Indication (%) Claud (17), CI (83) Claud (21), CI (79) Claud (34), CI (66)
Type of bypass (%) Fem-pop AK (53), BK (47) Fem-pop AK (36), BK (64) Fem-pop AK (37), BK (45), -crur (18)
Graft material (%) PTFE PTFE (70), Dacron (30) Vein (70), PTFE (30)
Year of publication 1982 1984 1984
A, Aspirin in daily dose (milligrams); D, dipyridamole in daily dose (milligrams); P, placebo; Ph, phenprocoumon and target INR; 
W, warfarin and target INR; Claud, intermittent claudication; CI, critical ischemia; Fem-pop, femoro-popliteal bypass; AK, above 
knee; BK, below knee; -crur, femoro-crural bypass; PTFE, polytetrafluoroethylene.
plications was also sought. Perioperative hemorrhag-
ic complications were not considered.
Data analysis. Two of the authors (MT and JL)
independently identified the trials to be included and
extracted relevant data. Discrepancies were resolved
with the help of a third author (AA), after which
decisions regarding entry of trials and data to be ana-
lyzed were made by consensus of all of the authors.
All trials were analyzed according to the inten-
tion-to-treat principle. The results are reported as
Mantel-Haenszel weighted estimates of the relative
risks (RRs) that were calculated by the fixed-effects
method, with corresponding 95% CIs.12 RRs small-
er than 1 indicate that the index treatment is better,
RRs larger than 1 favor control treatment. To assess
validity of pooling of these data, we performed a χ2
test for heterogeneity by means of a standard fixed-
effects method of meta-analysis.
In order not to overestimate the effects of treat-
ment, a supplementary meta-analysis according to
the worst case scenario was performed. In this sce-
nario it is assumed that those patients who have been
excluded or lost to follow-up in the index treatment
group have the worst possible outcomes, whereas
those patients who have been excluded or lost to fol-
low-up in the control group are considered to have
the best possible outcomes. If the estimation of
effects of the latter analysis differs importantly from
the outcomes of the meta-analysis, no definite con-
clusions about the effect of therapy may be drawn.
RESULTS
Antiplatelet therapy versus placebo. Five RCTs
comparing aspirin (with or without other antiplatelet
therapy) with placebo after infrainguinal bypass
surgery were included, resulting in a total of 816
patients (423 treated patients and 393 control sub-
jects).4,13-16 The design characteristics of the included
trials are given in Table I. All RCTs reported the num-
ber of occlusions and deaths systematically, but not
every trial reported the other clinical endpoints of
interest: stroke and myocardial infarction.
Six RCTs considered eligible for analysis were
excluded: in three RCTs patients after thromboen-
darterectomy and/or central reconstruction were
also randomized,19-22 in two RCTs patients were
treated for only 6 weeks or less,10,23 in one RCT
there was prior knowledge of the (nonblinded) next
treatment allocation because of randomization by
date of birth,24 and one trial did not systematically
study clinical endpoints, allowing intention-to-treat
analysis, but assessed progression of disease by eval-
uating arteriograms.25
All trials assessed the number of occlusions after
randomization (Fig 1). In every trial Doppler ultra-
sonography scanning was used to assess patency, fol-
lowed by angiography if indicated. In 423 patients
treated with antiplatelet drugs, 120 (28.4%) bypass-
es occluded compared with 144 (36.6%) occlusions
in 393 randomized control subjects. The RR is 0.78
(95% CI, 0.64-0.95), meaning a proportional risk
reduction of 22%. This corresponds with a signifi-
cant absolute risk reduction of 8.2%. There is sub-
stantial heterogeneity between the trials for this out-
come (χ2, 17.70; df = 4; P < .01).
Only three trials reported the number of strokes
during follow-up (Fig 2). Among 351 patients treat-
ed, there were 17 strokes compared with 19 strokes
among 312 control subjects, resulting in an RR of
0.80 (95% CI, 0.41-1.57). The same trials assessed
the occurrence of myocardial infarction during fol-
low-up (Fig 3). In the treated group fewer myocar-
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Donaldson16 McCollum4 Kretchmer17 Sarac18
A990 + D225, P A600 + D300, P Ph2.4-4.8, no treatment W2-3 + A325, A325
One day preoperative Two days preoperative One week postoperative W 2-3 days postoperative, 
A 1 day preoperative
33, 32 286, 263 66, 64 32, 24
12 36 120 36
12 36 120 36
Claud Claud (40), CI (60) Claud (48), CI (52) Claud (5), CI (95)
Fem-pop AK (68), BK (32) Fem-pop AK (41), BK (59) Fem-pop AK (43), BK (57) Fem-pop (9), -crur (91)
Dacron Vein Vein Vein
1985 1991 1992 1998
dial infarctions were reported: 25 among 351
patients compared with 34 among 312 control sub-
jects. The RR is 0.64 (95% CI, 0.37-1.10).
All trials reported both vascular and overall mor-
tality rates at the end of the follow-up period (Figs 4
and 5). Among 423 patients allocated to antiplatelet
treatment, 33 died of a vascular cause compared with
43 among 393 control subjects (RR, 0.71; 95% CI,
0.47-1.09), and therefore the absolute risk reduction
is 3.1%. The difference in total mortality is smaller. In
both groups 50 patients died (RR, 0.92; 95% CI,
0.64-1.32), with an absolute risk reduction of 0.9%.
Analysis of the composite outcome resulted in a
total of 62 patients who had a vascular event among
423 treated patients compared with 65 patients with
a vascular event among 393 control patients (RR,
0.88; 95% CI, 0.64-1.2; Fig 6). This corresponds
with an absolute risk reduction of 2%.
Bleeding complications related to medication
were reported in two trials. There were seven bleed-
ing complications in the treated patients versus five
bleeding complications in the control patients.4,13
One gastrointestinal bleeding complication in the
treatment group was fatal.
The results of a supplementary meta-analysis
according to the worst case scenario did not differ
essentially from those described above.
Oral anticoagulant treatment versus control.
Only one RCT studying the effects of oral anticoag-
ulation versus no treatment after venous infrain-
guinal bypass surgery met the inclusion criteria
(Table I).17 Two RCTs considered eligible for analy-
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Fig 1. Effect of antiplatelet therapy on bypass occlusion. Filled square, Area proportional to
amount of information contributed; filled diamond, result for total of trials.
Fig 2. Effect of antiplatelet therapy on stroke (nonfatal and fatal).
Fig 3. Effect of antiplatelet therapy on myocardial infarction (nonfatal and fatal).
sis were excluded because patients after thromboen-
darterectomy,26 central reconstruction, and conserv-
ative treatment were also randomized.27
In the included trial the effect of long-term treat-
ment with phenprocoumon on graft patency and
limb salvage was measured. Patency was determined
by Doppler ultrasonography scanning when indicat-
ed, followed by angiography. In 66 patients treated,
13 (19.7%) grafts occluded compared with 23
(35.9%) in 64 control subjects (RR, 0.55; 95% CI,
0.30-0.99), meaning a proportional risk reduction
of 45%. The corresponding absolute risk reduction is
16.2%. In the treated group there were four (6.1%)
amputations compared with 13 (20.3%) in the con-
trol group (RR 0.30, 95% CI, 0.10-0.87), with an
absolute risk reduction of 14.2%. The number of
strokes and myocardial infarctions were not report-
ed in this trial. Therefore estimation of the effects of
oral anticoagulants on the composite outcome was
also not possible. Among the anticoagulated
patients, 27 (40.9%) died during 10 years of follow-
up compared with 37 (57.8%) in the control group
(RR, 0.71; 95% CI, 0.49-1.01), resulting in an
absolute risk reduction of 16.9%. The study report-
ed one fatal gastrointestinal hemorrhage in the treat-
ed group.
Antiplatelet drugs versus oral anticoagulant
treatment. Only two trials of platelet inhibitors ver-
sus oral anticoagulants after infrainguinal bypass
surgery were found from which one did not fulfill
the inclusion criteria because of inclusion of patients
after thromboendarterectomy.28 In the included
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Fig 4. Effect of antiplatelet therapy on vascular mortality (including “unknown causes”).
Fig 5. Effect of antiplatelet therapy on total mortality.
Fig 6. Effect of antiplatelet therapy on the composite outcome.
trial 56 patients who were at high risk for graft fail-
ure were randomized to a combination of warfarin
and aspirin or aspirin only.18 Aspirin (375 mg daily)
was started 1 day preoperatively, and warfarin (inter-
national normalized ratio (INR), 2-3) was started 2
or 3 days postoperatively; patients in the warfarin
plus aspirin group received postoperative intra-
venous heparin. In 32 patients treated with warfarin
plus aspirin, five (15.6%) grafts occluded compared
with 10 (41.7%) grafts in 24 patients treated with
aspirin, with a corresponding RR of 0.38 (95% CI,
0.15-0.95). This equals a proportional risk reduc-
tion of 62%. In the warfarin plus aspirin group, five
amputations were reported compared with nine in
the aspirin group (RR, 0.42; 95% CI, 0.16-1.08).
The number of myocardial infarctions and deaths
were too small for reliable inferences on efficacy. In
the warfarin plus aspirin group, there were five
bleeding complications reported compared with
four bleeding complications in the aspirin group.
DISCUSSION
Today most of us agree on the benefit of
antithrombotic treatment in patients after infrain-
guinal bypass surgery. Supposed evidence for the
favorable effect of treatment in vascular surgical
patients comes from trials in various categories of
patients.11 Evidence for the measure of effect in this
particular group of patients is still weak, and there-
fore we undertook this meta-analysis.
Early graft failures are mostly related to technical
and hemodynamic factors. Various perioperative
antithrombotic drugs, like heparin, play an impor-
tant role in the prevention of early occlusion. The
goal of antithrombotic therapy is long-term preven-
tion of arterial occlusion to avoid various vascular
complications. Therefore we only included RCTs
prescribing long-term treatment.
We calculated RRs and absolute risks, the latter
reflecting the baseline risk, as well as the change in
risk with the intervention as a measure of effect to
avoid overestimation of effects and to facilitate clin-
ical interpretation. The reciprocal of the absolute
risk difference results in the number of patients
needed to be treated to prevent one event. Meta-
analysis of five RCTs of antiplatelet regimens versus
placebo showed a benefit for prevention of occlusion
in absolute terms of 8.2%, meaning that approxi-
mately 12 patients need to be treated for 1 to 3 years
to prevent one occlusion.4,13-16 The number of
myocardial infarctions, strokes, and deaths was too
low to draw any firm conclusion about the efficacy
of antithrombotic treatment to prevent these com-
plications. The absolute benefit for the composite
outcome was only 2%, implying that approximately
50 patients need to be treated with platelet
inhibitors for 1 to 3 years to prevent one such event.
There was substantial heterogeneity for the out-
come occlusion among the trials, indicating a differ-
ence in the estimates of effects between the studies. A
potential cause of this heterogeneity is the difference
in the number of patients randomized between the
studies. The effect size of the larger studies were not
conclusive,4,15 which was in contrast to the smaller
studies.13,14,16 Because of publication bias, there may
be selective inclusion of positive reports provided that
smaller studies are more likely to be published when
the results are favorable for treatment. Treatment was
started before surgery and restarted at the first day
after surgery in all trials, except for the trial by Kohler
et al,15 in which treatment was started at the first day
after surgery. However, the incidence of occlusion for
the treatment group was approximately the same as
in the other trials in the first 3 months: 8% occlusion
rate compared with 4%,14 6%,16 8%,13 and 14%.4 This
pleads against time of onset of treatment as a source
of heterogeneity. This finding is consistent with the
analysis by the Antiplatelet Trialists’ Collaboration,11
which failed to demonstrate a difference in reduction
of vascular occlusion when treatment was started
before or after a procedure. The excluded trial by
Clyne et al,23 in which antiplatelet therapy was given
only for 6 weeks, demonstrated benefit of treatment
only in patients with prosthetic grafts, whereas no
benefit of treatment was seen in the venous bypass
group. Also, in the included trials the type of graft
material seems to affect the outcome. In the trial by
Kohler et al,15 47% of the polytetrafluoroethylene
grafts occluded in the treated group, whereas 50% of
the polytetrafluoroethylene grafts occluded in the
placebo group (RR, 0.93). In the venous bypass
group 42% of the grafts occluded in the treated
group and 26% in the placebo group (RR, 1.62).
This trial demonstrated no benefit from antiplatelet
therapy in the patients with prosthetic grafts; howev-
er, this small group consisted of only 30% of the
patients, and therefore the effect estimate is impre-
cise. In the vein group the trial even demonstrated a
harmful trend of antiplatelet therapy on graft paten-
cy. On the other hand, the largest trial, by McCollum
et al,4 in which only patients with venous grafts were
included, showed a nonsignificant trend toward effi-
cacy of antiplatelet therapy in prevention of graft
occlusion (RR, 0.92). The trial by Goldman and
McCollum14 demonstrated a nonsignificant trend
toward benefit of antiplatelet therapy in patients with
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prosthetic grafts (RR, 0.52). A more clear effect of
antiplatelet therapy was shown in the trials by
Donaldson et al16 and Green et al13 in which only
patients with prosthetic grafts were included (RR,
0.26 and 0.35, respectively). Antiplatelet therapy
seems to be more effective in the prevention of occlu-
sion of prosthetic grafts than of vein grafts. This
modification of treatment effect by graft material may
therefore cause heterogeneity among the included
trials. Irrespective of the low statistical power of the
test for heterogeneity, the aggregated favorable
results for treatment with antiplatelet drugs must be
interpreted cautiously.
The results of the conducted supplementary
meta-analysis according to the worst case scenario
did not differ essentially from the results described
above. This indicates that the results of this meta-
analysis are not overestimated in favor of the patients
allocated to antiplatelet treatment.
The number of major bleeding complications
appeared to be modest. Two trials reported seven
bleeding complications (one fatal) in the antiplatelet
group and five bleeding complications in the place-
bo group.
The only RCT comparing the effects of oral anti-
coagulation therapy with no treatment after infrain-
guinal bypass surgery indicated that approximately
six patients need to be treated to prevent one occlu-
sion, and seven patients need to be treated to pre-
vent one amputation during a period of 10 years.17
The difference in survival was too small to reach sta-
tistical significance, but the trend was in favor of
treatment. Of 1432 prothrombin time measure-
ments, 12% to 14% were above the target INR of 2.4
to 4.8. Only one drug-related fatal bleeding compli-
cation was reported in 311 treatment years.
Only two trials comparing oral anticoagulants
with aspirin were found from which one was includ-
ed.18,28 This trial on the combination of oral antico-
agulants and aspirin versus aspirin only in high-risk
patients demonstrated a favorable effect of combina-
tion treatment in maintaining graft patency com-
pared with aspirin alone. Approximately four patients
need to be treated with oral anticoagulants in combi-
nation with aspirin for 3 years to prevent one occlu-
sion; however, the precision of this estimate is limit-
ed. The results cannot be generalized to all patients
after infrainguinal bypass grafting because only high-
risk patients were included.
The strength of meta-analysis exists in increasing
precision of an effect estimate by pooling data from
various trials. This meta-analysis demonstrated a
reduction of the risk of graft occlusion by antiplatelet
therapy and oral anticoagulants. Unfortunately, the
number of conducted RCTs is small, the number of
patients in most of these trials is small, and only a few
trials studied cardiovascular and cerebrovascular
events other than graft patency in spite of the fact
that these patients do have a high risk of fatal and
nonfatal myocardial and cerebral infarction.5-8,29
Furthermore, it is not clear which antithrombotic
treatment should be preferred after infrainguinal
bypass surgery to prevent vascular complications. The
overview by the Antiplatelet Trialists’ Collaboration11
did not provide any difference in efficacy among dif-
ferent antiplatelet regimens. Promising results were
recently achieved with a new generation of platelet
inhibitors. An RCT by Becquemin30 showed signifi-
cant improvement of cumulative 2-year patency of
infrainguinal vein bypasses in 122 patients treated with
ticlopidine (82%) compared with 121 patients who
received placebo (63%) also if differences between
treatment groups with regard to site of distal anasto-
mosis were taken into account. Unfortunately, the
study was too small to demonstrate a beneficial effect
of ticlopidine on other ischemic events studied. The
efficacy in reducing the risk of ischemic events of clopi-
dogrel (chemically related to ticlopidine) was com-
pared with that of aspirin in patients with ischemic
stroke, myocardial infarction, or peripheral arterial
occlusive disease in the CAPRIE study.31 The RR
reduction for the composite outcome of stroke,
myocardial infarction, and vascular death was highest
in the subgroup of patients with peripheral arterial dis-
ease: 23.8% (95% CI, 8.9-36.2) in favor of clopidogrel.
Unfortunately, this trial does not provide evidence on
the prevention of peripheral bypass graft occlusion.
In all included trials a high dose of aspirin was
administered, which is theoretically less effective than
a low dose. High levels of aspirin cause inhibition of
cyclooxygenase in endothelial cells in addition to
causing inhibition of cyclooxygenase in platelets and
thus thromboxane A2 synthesis, which is responsible
for platelet aggregation and vasoconstriction.32-35
This way endothelial prostacyclin production is
diminished.36,37 In contrast, prostacyclin is not only a
powerful inhibitor of platelet adhesion and aggrega-
tion but also a vasodilator.34,36,38 A recent world-wide
survey showed that of all surgeons questioned, 60%
used platelet-aggregating inhibitors, with the majori-
ty using low-dose aspirin (<325 mg daily) and 34%
using oral anticoagulants after infrainguinal vascular
surgery.39 A major disadvantage of the use of oral
anticoagulants is the risk of bleeding complications.
Patients need to be monitored conscientiously in anti-
coagulation clinics to secure adequate anticoagulation
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and to prevent adverse events. Because of a well-orga-
nized system of anticoagulation clinics, the use of oral
anticoagulants is widespread in The Netherlands.
In the era of evidence-based medicine, randomized
comparisons of antithrombotic agents with regard to
vascular complications are needed. This meta-analysis
provides evidence for the prevention of graft occlusion
with platelet inhibitors and oral anticoagulants.
Evidence for prevention of stroke, myocardial infarc-
tion, and vascular death is shown in various categories
of vascular patients,31,40 but only promising beneficial
trends could be demonstrated in this meta-analysis of
patients with infrainguinal bypasses. For reasons men-
tioned previously, placebo-controlled trials are no
longer indicated. A large randomized trial comparing
oral anticoagulants (target INR 3-4.5) with aspirin (80
mg daily) after infrainguinal bypass surgery with
regard to ischemic events and major bleeding compli-
cations is in progress.41 This trial will quantify the risks
and benefits of these treatment modalities clearly.
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